Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Valeant buys Amoun Pharma for larger slice of MENA market

Comes after Canadian firm recently bought Salix for $11bn

- PMLiVE

Nothing but a shell game

Is health insurance a rigged game?

- PMLiVE

Amgen’s Blincyto effective in broader leukaemia population

Could lead to further licences for the $178,000 blood cancer treatment

- PMLiVE

Anti-hypertensive market to slow in Asia-Pacific

New data shows the value will approach $20bn 2021

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

- PMLiVE

Study shows Otsuka’s TB drug works even in worst cases

Deltybaeffective even in cases that are unlikely to respond to any other drug

- PMLiVE

Brandicourt steers Sanofi onto a new heading

Unveilsmajor restructuring of the French pharma group

- PMLiVE

Consilium Strategic Communications appoints Chris Gardner

Former life sciences leader at Citigate Dewe Rogerson joins as partner

- PMLiVE

Novartis wins partial reprieve for Gilenya in Germany

IQWiG now minded to give a broader recommendation for the multiple sclerosis pill

- PMLiVE

GSK partners with new science hub the Francis Crick Institute

Will work with the biomedical facility on an 'open innovation' basis

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

- PMLiVE

Takeda files ‘oral Velcade’ for myeloma in US

Follow up could be the first pill approved for this rare cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links